AlphaQuest LLC Has $197,000 Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

AlphaQuest LLC lowered its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 77.5% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 7,661 shares of the company's stock after selling 26,401 shares during the period. AlphaQuest LLC's holdings in IDEAYA Biosciences were worth $197,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of IDYA. KBC Group NV grew its stake in IDEAYA Biosciences by 29.1% in the 3rd quarter. KBC Group NV now owns 2,274 shares of the company's stock valued at $72,000 after buying an additional 513 shares during the last quarter. Amalgamated Bank boosted its holdings in shares of IDEAYA Biosciences by 22.9% during the third quarter. Amalgamated Bank now owns 2,840 shares of the company's stock worth $90,000 after acquiring an additional 530 shares during the period. Rhumbline Advisers grew its position in shares of IDEAYA Biosciences by 0.5% in the fourth quarter. Rhumbline Advisers now owns 113,561 shares of the company's stock valued at $2,919,000 after purchasing an additional 585 shares during the last quarter. US Bancorp DE grew its position in shares of IDEAYA Biosciences by 67.2% in the third quarter. US Bancorp DE now owns 1,714 shares of the company's stock valued at $54,000 after purchasing an additional 689 shares during the last quarter. Finally, Assetmark Inc. increased its stake in shares of IDEAYA Biosciences by 2.5% during the fourth quarter. Assetmark Inc. now owns 45,269 shares of the company's stock worth $1,163,000 after purchasing an additional 1,084 shares during the period. Institutional investors and hedge funds own 98.29% of the company's stock.

Remove Ads

IDEAYA Biosciences Trading Up 1.3 %

NASDAQ IDYA traded up $0.23 on Thursday, hitting $18.44. 834,797 shares of the company's stock were exchanged, compared to its average volume of 818,831. The stock has a 50-day moving average of $21.55 and a 200-day moving average of $26.80. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of -5.59 and a beta of 0.76. IDEAYA Biosciences, Inc. has a 52 week low of $16.95 and a 52 week high of $46.40.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The company had revenue of $7.00 million during the quarter, compared to analyst estimates of $7.00 million. As a group, analysts predict that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on IDYA shares. Stephens reaffirmed an "overweight" rating and issued a $50.00 price objective on shares of IDEAYA Biosciences in a report on Friday, February 14th. Cantor Fitzgerald restated an "overweight" rating on shares of IDEAYA Biosciences in a research note on Monday, January 13th. Royal Bank of Canada reiterated an "outperform" rating and issued a $61.00 price objective on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Finally, Wedbush reissued an "outperform" rating and issued a $52.00 price objective on shares of IDEAYA Biosciences in a report on Tuesday, December 17th. Two investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $53.58.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.